###### Strengths and limitations of this study

-   No randomised controlled trial investigating the effects of implementing an integrated medicines management-based intervention in the Norwegian healthcare setting has yet been published.

-   National healthcare registries will enable us to collect high-quality data for several outcomes including the primary outcome.

-   Collecting outcomes for a 1-year period after discharge allows us to measure sustainable effects of the intervention.

-   Including control and intervention patients from the same wards may introduce education and contamination bias.

-   As the intervention is complex this study will not allow for studying whether any of the specific steps are more or less responsible for any observed effects.

Introduction {#s1}
============

Healthcare systems across the world are challenged by an ageing population. Ageing is frequently accompanied by morbidity, which increases the need for pharmacotherapy. The increased complexity of medication regimes combined with frailty, reduced cognitive function and changes in pharmacokinetics and pharmacodynamics increases the risk of adverse drug events and other drug-related problems (DRPs) in this population.[@R1]

A DRP is 'an event or circumstance involving drug therapy that actually or potentially interferes with desired health outcomes'.[@R3] DRPs include inappropriate prescribing (drug, dose, dosage frequency and dosage form), drug interactions, adverse drug reactions, wrong administration, need for monitoring as well as non-adherence to medication therapy. DRPs occur frequently in the elderly,[@R4] and are associated with an increased risk of hospitalisation, morbidity and mortality.[@R6] For instance, adverse drug events alone contribute to 30%--40% of acute hospital admissions in the elderly,[@R9] many of them being preventable.[@R11]

Communication barriers across primary and secondary care, multiple prescribers, fragmentation of care and frequent transitions across care levels make hospitalised elderly in particular risk of drug-induced harm.[@R15] To improve the medicines management process in hospitals, pharmacist-dependent methods like medication reconciliation (MedRec), medication review and patient education have been developed and studied.[@R17] The integrated medicines management (IMM) model is based on interdisciplinary collaboration where clinical pharmacists work together with physicians, nurses and patients aiming to optimise medication therapy by preventing and solving DRPs.[@R21] In the IMM model different services like MedRec, medication review, patient counselling and dissemination of correct medication information at transition points are merged together in a systematic way.[@R21] In Northern Ireland, the implementation of the IMM model in hospitals has led to a reduced length of hospital stay and an increased time to readmission compared to standard care.[@R23] Also in Sweden, implementing IMM in single hospital settings has been associated with a reduction in readmissions and drug-related readmissions, improved communication of medication information at transition points and improved quality of medication therapy.[@R21] In Norway, pharmaceutical care services in hospitals have since 2010 been based on the methodology embraced by the IMM model.[@R27] However, no randomised controlled trial investigating the effects of implementing the IMM model in the Norwegian healthcare system has been published.

Based on the IMM model, we have designed an interdisciplinary collaboration structure aiming to optimise medication therapy in hospitals and to improve communication of medication-related issues between secondary and primary care. The aim of the study is to explore the effects of the intervention on healthcare use, health-related quality of life (HRQoL) and medication appropriateness in elderly patients.

Objectives {#s1a}
----------

The primary objective is to investigate the effects of the intervention on rate of emergency medical visits (acute readmissions and visits to emergency departments (EDs)) 12 months after hospital discharge.

Secondary objectives include to investigate the effects on: self-reported HRQoL, acute readmissions, length of index hospital stay, time to first readmission, 30-day readmissions, general practitioner (GP) visit rate, mortality rate, medication appropriateness, medication-related readmissions, medication changes, hip fracture rate and stroke rate.

Methods and analysis {#s2}
====================

This protocol is developed in accordance with the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) 2013 statement[@R28] (see online [supplementary file](#SP1){ref-type="supplementary-material"} for SPIRIT 2013 checklist).
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Study design {#s2a}
------------

This is a non-blinded randomised controlled trial with an intervention group and a control group (1:1 ratio). The intervention group receives the intervention, while the control group receives standard care, see [figure 1](#F1){ref-type="fig"}. Study enrolment started in September 2016.

![Flow chart of the study and study participants.](bmjopen-2017-020106f01){#F1}

Settings {#s2b}
--------

The study is carried out at two acute internal medicine wards at the University Hospital of North Norway (UNN); a geriatric internal medicine ward at UNN Tromsø and a general acute internal medicine ward at UNN Harstad. The geriatric ward cares for older patients with complex acute medical needs and has consultants specialised in geriatric medicine. The general medicine ward treats patients admitted for stroke, pulmonary, kidney and endocrine diseases as well as patients with geriatric concerns.

Study population {#s2c}
----------------

All acutely admitted patients are screened for eligibility and recruited by study pharmacists. Only eligible patients are invited to participate in the study. When written informed consent is obtained from patient or next of kin, the patient is included. Enrolment is only performed when a pharmacist is present. Readmitted study patients are not reincluded, but receive standard care.

Eligibility criteria {#s2d}
--------------------

Inclusion criteria: age ≥70 years, acutely admitted and willing to provide written informed consent (patient or next of kin). Exclusion criteria: admitted to the study ward more than 72 hours before evaluation of eligibility, moved to and discharged from other wards during the index stay, inability to understand Norwegian (patient or next of kin), considered terminally ill or with a short life expectancy, planned discharged on the inclusion day, occupying a bed in a study ward but under the care of physicians from a non-study ward or if an intervention from a study pharmacist is considered necessary for ethical reasons (before randomisation or in control group).

Randomisation and blinding {#s2e}
--------------------------

After collecting baseline data, patients are randomised into the two study arms using a web-based service supplied by a third party. The randomisation block sizes are concealed and permuted. We stratify by study site. As pharmacists are only involved in intervention patients, blinding of group allocation is impossible for both the patients, pharmacists and medical team. However, the primary analysis will be performed by an investigator blinded for group allocation.

Standard care (control group) {#s2f}
-----------------------------

Patients assigned to standard care receive treatment from a team consisting of physicians, nurses, nurse assistants, and sometimes occupational therapists and physiotherapists. Standard care may include elements as MedRec, medication review and patient counselling performed by physicians or nurses during the hospital stay. However, it is not standardised, structured or involving pharmacists. Study pharmacists are not involved in any clinical work concerning patients randomised to the control group.

Regarding MedRec at admission, this service is currently being implemented in hospitals nationwide as a part of the national patient safety programme. The local hospital procedure at UNN states that MedRec should be performed by a physician at admittance, but local data show that adherence to the procedure is low (data not published). Local procedures for communication of medication information at hospital discharge require that a discharge summary, including an updated medication list in addition to assessments, amendment and recommendations made during the hospital stay, is submitted electronically to the GP at discharge. For patients living in nursing homes or arecared for by the home care services, ward nurses call the home care services or nursing homes to inform about current medication therapy and to investigate the need for prescriptions or medications to be sent home with the patient. The GP is responsible for the follow-up of discharge summary recommendations as well as renewal and revision of prescribed medications.

Patients, for whom special home care is considered necessary, may be referred to a specialised patient care team before or at discharge. This team may include a pharmacist, which may supply pharmaceutical care services.

The intervention {#s2g}
----------------

Patients randomised to the intervention group receive the IMM-based intervention including: (1) MedRec at admission, (2) medication review and monitoring during the hospital stay, (3) patient counselling designed to meet the needs of each individual patient, (4) MedRec at discharge together with an updated and structured medication list given to patients and submitted to primary care at discharge and (5) a follow-up phone call to the patient's GP and nurses in home care service/nursing home to inform about and discuss current medication therapy and recommendations, see [figure 2](#F2){ref-type="fig"}. Step 5 is in addition to the original IMM model. The study pharmacist is performing all steps in close collaboration with the hospital physician who has the medical responsibility for the patients.

![The intervention based on the IMM model (steps 1--4)[@R21]. Step 5 is added to the original model. IMM, integrated medicines management; MedRec, medication reconciliation.](bmjopen-2017-020106f02){#F2}

### Step 1: medication reconciliation {#s2g1}

MedRec is performed using a standardised MedRec tool developed in Sweden and adapted to Norwegian circumstances/conditions.[@R21] The tool facilitates information collection about the patient's medication use and serves as documentation of information and information sources. It also includes questions about the patients practical handling and knowledge about medications, as well as medication adherence.[@R21] Patients that handle their own medication are interviewed if possible. If not, information about medication use is collected from other relevant sources, that is, medication lists from GPs, national electronic medical records, local pharmacies, home care services, nursing homes or next of kin. These sources are also used to confirm medication information after patient interviews in case of uncertainties. Any adherence or medication information issues identified during MedRec is acted on during patient counselling or at hospital discharge (step 3).

During MedRec, the study pharmacists also perform a standardised symptom assessment to be used in step 2. This is done to identify possible adverse drug reactions, or possible targets for medication therapy improvements from a patient perspective. The assessment is performed to reveal if a patient recently has experienced any of the following 10 symptoms potentially related to medication therapy: dizziness, general fatigue, memory deficiency, sleeping difficulties, dry mouth, nausea, constipation, micturition difficulties, pain or cough. If the patient is incapable of answering the questions, information is obtained from relatives or associated healthcare workers.

### Step 2: medication review {#s2g2}

Medication review is based on information collected during MedRec, clinical and laboratory data and other relevant information. It is regularly updated during the hospital stay as long as the study pharmacists are present at the ward. A standardised tool, developed in Sweden and adapted to Norwegian circumstances/conditions, is applied to identify DRPs related to the following risk categories[@R21]: (1) medications requiring therapeutic drug monitoring, (2) potential inappropriate medications for elderly, (3) problems related to drug administration/dosage forms, (4) drug interactions, (5) dose or medications not suitable for the individual patient (eg, renal or liver failure), (6) lack of indication for drug therapy, (7) appropriate length of therapy for temporarily used medications, (8) suboptimal treated or untreated diagnosis or symptoms, (9) medications causing adverse drug reactions or change in laboratory measurements and (10) other needs for monitoring of treatments. Identified DRPs are discussed and solved in the interdisciplinary team and with the patient if possible. DRPs not dealt with or solved during the hospital stay are communicated to the GP as part of the discharge summary together with recommendations and monitoring needs. Identified DRPs are classified according to the validated Norwegian classification system.[@R30]

### Step 3: patient counselling {#s2g3}

For patients who will handle their own medication after discharge, a patient counselling session is arranged before discharge. The patients receive an updated medication list, which is discussed and explained. The pharmacists focuses on changes made during the hospital stay and reasons for these changes. Patients are also encouraged to ask questions about their medications. Any medication adherence, handling or information issues identified during the hospital stay is also focused on. If DRPs are identified during this counselling session, they are discussed with the responsible physician. This step does not replace the standard discharge meeting between the physician and the patient.

### Step 4: structured and detailed medication list in discharge summaries {#s2g4}

The discharge summary normally includes an updated overview of medications to be used after discharge. For intervention patients the study pharmacists draft this list in accordance with hospital procedures and recommendations from the national patient safety programme. They make sure it is reconciled, structured and correct according to amendments done and include information and explanations about medication changes made during the hospital stay as well as recommendations and follow-up issues. The responsible ward physician uses this draft when preparing the discharge summary.

### Step 5: communication with primary care {#s2g5}

Within a week after discharge, the pharmacists call the patient's GP to inform about and discuss current medication therapy changes and recommendations stated in the discharge summary. The aim is to ensure that the changes and recommendations are implemented and acted upon.

One the day of discharge, for patients where the home care services or the nursing home administer the patient's medications, the pharmacists call the responsible nurse to inform about medication changes, prescription and monitoring needs and other medication-related recommendations. Changes in multidosage dispensed medications are submitted to the local pharmacy responsible for dispensing the patient's medications in agreement with the home care services.

This step is not carried out for patients with no change in medications during the hospital stay and/or no identified need for follow-up.

Outcomes {#s2h}
--------

### Primary outcome {#s2h1}

The primary outcome is the rate of 'acute readmissions and ED visits' 12 months after discharge from the index hospital stay in the intervention group compared with the control group. An acute readmission is defined as any subsequent admission following the index admission excluding elective readmissions.

### Secondary outcomes (intervention group compared with control group) {#s2h2}

1.  Change in self-reported HRQoL from discharge to 1, 6 and 12 months after hospital discharge.

2.  Length of index hospital stay.

3.  Time to first acute readmission after discharge from index hospital stay (up to 12 months follow-up).

4.  The proportion of patients readmitted acutely within 30 days (a national quality indicator in Norway).

5.  GP visit rate during 12 months' follow-up.

6.  Mortality rate during 12 months' follow-up.

7.  Change in total score of the Medication Appropriateness Index (MAI) from admission to discharge.

8.  Change in potentially inappropriate medications prescribed identified by The Norwegian General Practice---Nursing Home criteria (NORGEP-NH), Screening Tool of Older Persons' Prescriptions (STOPP) V.2 and Screening Tool to Alert doctors to Right treatment (START) V.2 from admission to discharge.

9.  Change in potentially inappropriate medications prescribed using START V.2, STOPP V.2 and NORGEP-NH from discharge to 3 and 12 months.

10. Medication changes made during index hospital stay implemented by the GP at 3 and 12 months.

11. Medication-related first readmissions after index hospital stay.

12. Hip fracture rate during 12 months' follow-up.

13. Stroke rate during 12 months' follow-up.

Sample size calculation {#s2i}
-----------------------

Sample size calculation for the primary outcome is based on a Swedish randomised controlled trial applying the same composite endpoint.[@R12] The Swedish trial investigated the effectiveness of interventions performed by ward-based pharmacists in reducing morbidity and use of hospital care among patients 80 years and older. They randomised 400 patients in a 1:1 relationship and found a 16% reduction in all-cause visits to the hospital in the intervention group. If we estimate a rate of acute hospital admissions and ED visits of 1.7 per year in our control group, we need to enrol 456 patients (228 in each group) to detect a 16% reduction in hospital visits with a significance level of 5% and a power of 80%. To compensate for dropouts, we aim to include 250 patients in each group.

Data collection and tool application {#s2j}
------------------------------------

### Baseline {#s2j1}

Baseline data for all study patients is collected before randomisation to avoid collection bias. This include age, gender, smoking status, marital status, level of education, type and amount of help from home care services, and delivery of multidosage dispensed medications, medical diagnosis/medical history, weight, blood pressure, heart rate, relevant laboratory values (eg, blood creatinine, C reactive protein, haemoglobin and glucose) and medication use at time of hospital admission. The latter is denoted in the handwritten medication chart as standard procedure in our hospitals, while all other information is found in the electronic patient journal.

### Hospital stay {#s2j2}

For the intervention group only, we collect outcome data from the intervention (eg, discrepancies identified during MedRec, DRPs, physician agreement with regard to identified discrepancies or DRP, counselling issues, etc) during hospitalisation and track communication between pharmacist, patients and healthcare workers in the ward and in primary care. For all study patients, we collect the following data from the discharge summary: discharge diagnose(s), laboratory results, medication list including description of changes during the hospital stay and recommendations to the next care level.

### After discharge {#s2j3}

Data collection of outcomes after discharge is identical for all study patients.

### National registries {#s2j4}

Data on readmissions (dates, lengths and reasons), ED visits (dates and reasons), GP visits (dates and reasons), deaths (date and reason), strokes (dates), hip fractures (dates and reasons) and dispensed medications will be collected from six Norwegian Health registries. These registries are, respectively: The Norwegian Patient Registry (hospitalisations and ED visits), The Norwegian Health Economics Administration Registry (ED and GP visits), the National Cause of Death Registry, the Norwegian Stroke Registry, the Norwegian Hip Fracture Registry and the Norwegian Prescription Database (NorPD) holding information about all pharmacy dispensed medications in Norway. Linking data is possible through the unique personal identification number held by every Norwegian citizen. ED visits leading to a hospital stay will be counted as a hospital stay. We will collect data from all registries for the period 12 months before and 12 months after index hospital stay to enable adjustment for prestudy patterns.

### Medication use {#s2j5}

In addition to the data on prescriptions collected from NorPD, updated lists of medications in use are collected from GP offices or nursing homes as appropriate at 3 and 12 months after hospital discharge.

### Inappropriate prescribing {#s2j6}

The medications lists at hospital admission, at discharge and at 3 and 12 months after discharge will retrospectively be subjected to application of the following scoring tools to identify possible inappropriate prescribing by an investigator blinded for group allocation: NORGEP-NH,[@R31] STOPP and START.[@R32] The medication lists at admission and at discharge will be scored in accordance with the MAI by an experience pharmacist blinded to group allocation.[@R33]

### Health-related quality of life {#s2j7}

We use EuroQol 5 dimension (EQ-5D) and EuroQol visual analogue Scale (EQ-VAS) to measure HRQoL.[@R35] This is performed by a study nurse blinded to group allocation. The measurement is performed at the end of the hospital stay and 1, 6 and 12 months after discharge. The study nurse calls patients and performs the interview by phone. Patients where next of kin provide informed consent are excluded from this measure. We collect information about need for home care services/nursing home at 1, 6 and 12 months to adjust for in the HRQoL analysis.

### Medication-related readmissions {#s2j8}

An interdisciplinary group of physicians and pharmacists will retrospectively assess whether the patient's first readmission was related to his/her medications and whether it could have been prevented. This will be performed blinded to group allocation.

Data management {#s2k}
---------------

All data, except registry data, are entered manually into a Microsoft Access database. A random sample of patients will be drawn for control of data quality. Patient-ID is removed from all paper records and given consecutive study numbers. A list linking patient-IDs to study numbers is stored electronically on the hospital research server, separate from the Microsoft Access database. Only study personnel have access to the research server. Study papers used during work are kept at the hospital in accordance with hospital's patient protection routines.

Statistical analysis {#s2l}
--------------------

We will use IBM SPSS Statistics V.25 for data analysis. Data will be analysed according to intention-to-treat principle, and the reporting of results will follow the Consolidated Standards of Reporting Trials guidelines.[@R36] All participants will be included in the analysis, regardless of whether the intervention was completed or not. A per-protocol analysis will also be performed. Descriptive statistics for both study arms and the total study population will be provided.

The primary analysis will be a Poisson regression of the rate of the composite endpoint during 12 months after discharge between the two study groups. Censoring of study participants will be accounted for, and adjustment for study site will be conducted. A two-sided alpha level of 5% will be used. We will perform a secondary analysis of the primary endpoint using the proportion of patients fulfilling the composite endpoint and a survival analysis of the time to reach the composite endpoint. In all analyses, adjustment for baseline variables will be conducted if appropriate.

We will analyse secondary outcomes applying appropriate statistical tests, for example, comparison between study arms by logistic regression analysis for binary responses and using Cox proportional hazards models for survival data. Continuous responses will be analysed using linear regression. A two-sided 5% significance level will be applied, with no adjustments for multiplicity.

The amount of data collected allows for different subgroup analyses and include: to assess whether the effect of the intervention varies by: (1) number of medications at admission or discharge; 0--5, 6--10, \>10, (2) age groups 70--79, 80--89 and 90+, (3) patient responsibility for their own medication at discharge, (4) number and type of comorbidities at discharge, (5) number of hospital visits prior to inclusion, (6) length of hospital stay, (7) referred from home, home-care or nursing home or (8) able to self-provide informed consent or not.

Ethics and dissemination {#s3}
========================

The trial will be conducted in compliance with the protocol, the principles of Good Clinical Practice and the Declaration of Helsinki. Only patients who supply a written informed consent are included in the study. If patients are not able to consent, the next of kin is asked. If a patient is temporarily incapable of giving consent, for instance in the case of delirium, consent is first sought from the next of kin. If and when the patient is again considered able to consent he/she is asked to give the written consent themselves. Patients who refuse participation are excluded from the study.

We will not expose the patient for any new clinical intervention that may put the patient at risk. In fact, some of the elements/procedures included in the intervention have already been shown to reduce drug-related readmissions, and visits to the ED.[@R19] Nevertheless, our intervention brings a new healthcare profession, the pharmacist, into the interdisciplinary team for whom the patient will have to relate to. We anticipate that patients feeling uncomfortable with this will refuse study participation.

We aim to publish study results in international peer-reviewed open access journals, at national and international conferences, and as part of two PhD theses.
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